- Home
- HOLO vs SCYX Comparison
HOLO vs SCYX Comparison
Compare HOLO & SCYX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HOLO
- SCYX
- Stock Information
- Founded
- HOLO 2018
- SCYX 1999
- Country
- HOLO China
- SCYX United States
- Employees
- HOLO N/A
- SCYX N/A
- Industry
- HOLO Computer Software: Programming Data Processing
- SCYX Biotechnology: Pharmaceutical Preparations
- Sector
- HOLO Technology
- SCYX Health Care
- Exchange
- HOLO Nasdaq
- SCYX Nasdaq
- Market Cap
- HOLO 24.9M
- SCYX 28.5M
- IPO Year
- HOLO N/A
- SCYX 2014
- Fundamental
- Price
- HOLO $5.12
- SCYX $0.73
- Analyst Decision
- HOLO
- SCYX
- Analyst Count
- HOLO 0
- SCYX 0
- Target Price
- HOLO N/A
- SCYX N/A
- AVG Volume (30 Days)
- HOLO 4.7M
- SCYX 197.3K
- Earning Date
- HOLO 01-01-0001
- SCYX 08-07-2025
- Dividend Yield
- HOLO N/A
- SCYX N/A
- EPS Growth
- HOLO N/A
- SCYX N/A
- EPS
- HOLO N/A
- SCYX N/A
- Revenue
- HOLO $39,771,750.00
- SCYX $2,630,000.00
- Revenue This Year
- HOLO N/A
- SCYX $410.22
- Revenue Next Year
- HOLO N/A
- SCYX $248.83
- P/E Ratio
- HOLO N/A
- SCYX N/A
- Revenue Growth
- HOLO 42.62
- SCYX N/A
- 52 Week Low
- HOLO $4.16
- SCYX $0.66
- 52 Week High
- HOLO $608.00
- SCYX $2.21
- Technical
- Relative Strength Index (RSI)
- HOLO 44.22
- SCYX 46.63
- Support Level
- HOLO $5.07
- SCYX $0.67
- Resistance Level
- HOLO $5.59
- SCYX $0.83
- Average True Range (ATR)
- HOLO 0.85
- SCYX 0.04
- MACD
- HOLO 0.03
- SCYX 0.01
- Stochastic Oscillator
- HOLO 4.32
- SCYX 37.56
About HOLO MicroCloud Hologram Inc.
MicroCloud Hologram Inc, through its subsidiaries, is mainly engaged in holographic Technology. It includes Holographic solutions and Holographic technology services. The company also provides holographic digital twin technology services for customers and has built a holographic digital twin technology resource library. Geographically company is operating in single segment, China.
About SCYX SCYNEXIS Inc.
SCYNEXIS Inc is a drug development company that focuses on the development and commercialization of novel anti-infectives to address unmet therapeutic needs. It is engaged in developing a product candidate, ibrexafungerp which is a novel oral and intravenous (IV) drug for the treatment of several fungal infections, including serious and life-threatening invasive fungal infections. The ibrexafungerp is a novel and structurally distinct triterpenoid glucan synthase inhibitor that is effective in vitro and in vivo against broad range of Candida and Aspergillus species, including drug-resistant strains as well as Pneumocystis, Coccidioides, Histoplasma and Blastomyces genera and some common mucorales species.